The Future of Follicular Lymphoma Treatment Runs Through the Pharma Industry
Lymphoma refers to the cancer of lymphatic system, which affects the cells of the immune system known as lymphocytes resulting into abnormal multiplication and growth of the cells. Lymphocytes are the white blood cells that protects the body from the infection. It is of two types, namely, Non-Hodgkin and Hodgkin lymphoma. Follicular lymphoma is a type of Non-Hodgkin Lymphoma that affects the lymphocytes. It is the most common indolent type of Non- Hodgkin lymphoma. Follicular lymphoma has symptoms such as enlargement of the lymph nodes in the neck, groin, and abdomen, shortness of breath, weight loss, night sweats, and fatigue.
To get holistic SAMPLE of the report, please click: https://www.coherentmarketinsights.com/insight/request-sample/907
Follicular lymphoma can be treated on the basis of the acuteness of associated symptoms and on cancer growth rate. Radiation and chemotherapy are presently the responsive treatment for follicular lymphoma. However, radiation alone can be used for the treatment of follicular lymphoma in most of the cases. In more advanced cases chemotherapy or a monoclonal antibody rituximab, alone or the combination of both are used for the treatment of follicular lymphoma. Moreover, monoclonal antibodies are more predominant over the chemotherapy, as they act directly by targeting on tumor cells and thereby, increases immune cells that destructs tumor, which increases response to the treatment.
Rituximab a monoclonal antibody used as a therapeutic agent is expected to augment the market growth
The major factors contributing to the growth of global follicular lymphoma treatment market are rising adoption of monoclonal antibodies for targeted therapies. According to the National Center for Biotechnology Information (NCBI), in 2016, monoclonal antibodies are considered as the successful therapeutics in the cancer treatment. The use of monoclonal antibodies is expected to overcome the side effects, which are generally exhibited by traditional therapies such as radiation and chemotherapy. Therefore, the monoclonal antibody such as rituximab, an anti-CD20 antibody can act as a potential therapeutic agent for the treatment of follicular lymphoma cancer. Moreover, increase in the number of incidence of relapsed follicular lymphoma is also expected to drive the market growth as the number of relapse for the disease results in the same patient availing the treatment multiple times. However, the factors hindering the growth of follicular lymphoma treatment market are the availability of the drugs and high cost of the treatment.
Rising prevalence of follicular lymphoma cases is expected to fuel the market growth in North America
On the basis of geography, the global follicular lymphoma treatment market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global follicular lymphoma treatment market, owing to the rise in the follicular lymphoma cases. According to the American Cancer Society (ACS), in 2017, around 72,240 people including adults and children are expected to get diagnosed with follicular lymphoma. Moreover, a series of studies are initiated in the National Cancer Institute, in U.S., to assess the novel emerging sequencing technologies in cancer, as part of the cancer genome characterization. Furthermore, Asia Pacific is expected to hold a major market share in the global follicular lymphoma treatment market over the forecast period. This is mainly owing to advanced research practices adopted by the government and private research institutes of China to curb the follicular lymphoma cancer.
To get detailed table of content (ToC), please click: https://www.coherentmarketinsights.com/ongoing-insight/toc/907
The innovative Drug Aliqopa launched by Bayer AG’s is expected to propel the market growth
Some of the key players operating in the global follicular lymphoma treatment market include Roche, Spectrum Pharmaceuticals, Johnson and Johnson, CTI Biopharma, Celgene, AbbVie Inc., Novartis, Amgen, Merck & Co. (MRK), Seattle Genetics, Pharmacyclics/ Bristol-Myers Squibb (BMY), and Bayer AG’S. In 2017, Bayer AG’s has launched an innovative drug, Aliqopa, also known as copanlisib, which is a kinase inhibitor that block certain enzymes responsible in promoting cell growth.
You may be interested
Dental Implants Market to Develop Rapidly by 2018 – 2026Albert R - August 21, 2018
Dental Implants Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market share,…
Latest Evolution of Geriatric Care Services Market Analysis 2026Albert R - August 21, 2018
Geriatric Care Services Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market…